Member Posts > Cardiol Therapeutics' CRD-38 and Its Dual Mechanism for Enhancing Mitochondrial Function in HF
Mitochondrial dysfunction is a critical factor in the development of heart failure (HF), leading to energy depletion and increased oxidative damage. Cardiol Therapeutics is pioneering a novel approach with CRD-38, a cannabidiol-based therapy that targets mitochondrial impairment in HF patients. CRD-38 exerts its beneficial effects through two primary mechanisms: (1) reducing oxidative stress via CBD's anti-inflammatory action, which helps prevent further mitochondrial degradation, and (2) activating peroxisome proliferator-activated receptor gamma (PPAR-γ), a key regulator of mitochondrial biogenesis that improves ATP production and energy utilization in cardiac cells. Preclinical studies have confirmed that CRD-38 enhances mitochondrial respiration, preserves cardiomyocyte function, and improves overall cardiac output. Given the metabolic inefficiencies associated with HFpEF, CRD-38 could offer a much-needed therapeutic solution. With Cardiol Therapeutics preparing for clinical trials, this therapy could potentially redefine heart failure management.

#CardiolTherapeutics #HeartFailureTreatment #BiotechInvesting #ClinicalTrials #CBDTherapeutics #HeartHealth #MedicalInnovation #PharmaceuticalBreakthroughs #CRD38